Astrazeneca plc is buying 55 percent of privately held Acerta Pharma LLC, the developer of acalabrutinib, a phase III oral small-molecule Bruton's tyrosine kinase (BTK) inhibitor that it expects to transform the treatment of B-cell malignancies.